| Name | Title | Contact Details |
|---|---|---|
Donna Rill |
Chief Technology Officer | Profile |
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Kansas City University announced June 4 its plans to open a College of Dental Medicine on its Joplin, Missouri, campus, with an anticipated groundbreaking in 2020. The goal is to seat a class of 80 students in 2022.
Provident Clinical Research and Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.